Item 8.01 Other Events.
On September 7, 2021, Selecta Biosciences, Inc. (the "Company") entered into a
Collaboration and License Agreement (the "Agreement") with Cyrus Biotechnology,
Inc. ("Cyrus"). Under the Agreement, Cyrus agreed to grant the Company an
exclusive, worldwide license to certain intellectual property in order to form a
protein engineering collaboration combining the Company's ImmTOR platform with
Cyrus' ability to redesign protein therapeutics. The lead program in the
collaboration is a proprietary interleukin-2 (IL-2) protein agonist designed to
selectively promote expansion of regulatory T cells for the treatment of
patients with autoimmune diseases and other deleterious immune conditions. The
Company expects that novel engineered protein therapeutic candidates from the
partnership will be used to expand the Company's proprietary pipeline and
further bolster its ImmTOR platform.
In return for the licensed intellectual property, Selecta is obligated to make
an upfront payment and pay certain discovery, development, and sales-based
milestones which could potentially total up to approximately $1.5 billion across
multiple programs.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses